TE‐1146, like its “parent” daratumumab, showed specific and dose‐dependent binding to U266‐CD38+ and H929 cells (Figure 3d) as well as MM.1S cells, but not to U266‐CD38− MM cells (Figure S6a–c, Supporting Information). Here, CD38 is linked to Miyoshi myopathy.